Evotec CFO Paul Hitchin to Step Down on April 30
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy EVO?
Evotec announced that CFO Paul Hitchin will step down on April 30 for personal reasons unrelated to the company. The supervisory board has accepted Hitchin's decision. Hitchin will be succeeded by Claire Hinshelwood, effective May 1. Hinshelwood has more than 30 years of experience in financial leadership positions, most recently as group CFO of BMI Group.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EVO
Wall Street analysts forecast EVO stock price to rise
3 Analyst Rating
2 Buy
0 Hold
1 Sell
Moderate Buy
Current: 3.230
Low
5.00
Averages
6.00
High
7.00
Current: 3.230
Low
5.00
Averages
6.00
High
7.00
About EVO
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Evotec CFO Paul Hitchin Resigns, Claire Hinshelwood Appointed
- Executive Change: Evotec SE announced that CFO Paul Hitchin will resign on April 30, citing personal reasons unrelated to the company, indicating potential challenges in executive stability.
- New Financial Chief: Claire Hinshelwood will take over as CFO on May 1, bringing over 30 years of financial leadership experience, particularly from her recent role as CFO at BMI Group, which is expected to introduce new financial strategies for the company.
- Stock Price Reaction: On Nasdaq, Evotec's shares rose 1.55% in after-hours trading to $3.28, reflecting market optimism regarding the new CFO's appointment, despite closing at $3.23 during regular trading.
- Market Confidence: Although executive changes can introduce uncertainty, the market's response suggests that investors maintain a positive outlook on Evotec's future financial management and strategic direction, which may influence its long-term stock performance.
See More
Evotec Appoints New Chief Operating Officer
- Executive Appointment: Evotec announced the appointment of Dr. Ingrid Müller as Chief Operating Officer, effective May 1, 2026, bringing over 20 years of international leadership experience to oversee global operations and the execution of the Horizon initiative.
- Strategic Execution: In her previous role as Vice President at CureVac, Dr. Müller successfully drove portfolio strategy and execution, and in senior roles at Sanofi and Fresenius Kabi, she strengthened supply chain resilience and achieved annual savings.
- Operational Efficiency Enhancement: As COO, Dr. Müller will focus on improving quality, productivity, and delivery capabilities, with expectations that her extensive operational and strategic background will drive Evotec's growth transformation and enhance its competitiveness in the life sciences sector.
- Global Team Collaboration: Dr. Müller expressed her eagerness to collaborate with the global team to further enhance operational excellence and quality, supporting Evotec's sustainable growth and reflecting the company's commitment to scientific and technological platforms.
See More
Evotec (EVO) Q3 2025 Earnings Call Transcript
See More
Evotec SE Reports Significant Revenue and Cost Savings in 2025
- Revenue Growth: In Q4 2025, Evotec SE reported a revenue increase of EUR 32.1 million, or 14.5%, reaching EUR 253.3 million, indicating strong market performance despite a slight 1.1% decline in full-year revenue.
- Significant EBITDA Improvement: Adjusted EBITDA surged by EUR 29.5 million, or 103.6%, to EUR 58 million in Q4 2025, reflecting substantial operational efficiency improvements that enhance financial resilience.
- Cost Savings Achieved: Evotec delivered over EUR 60 million in annualized cost savings in 2025 and reduced capital expenditures by approximately 60%, providing more funding for future investments and growth opportunities.
- Strategic Partnership Agreements: The $650 million agreement with Sandoz and milestone payments from BMS signify crucial advancements in Evotec's global health programs, expected to drive future revenue growth.
See More
Evotec Nominates New Chairman for Supervisory Board
- Board Leadership Change: Evotec SE has nominated Dieter Weinand as Chairman of the Supervisory Board, with the election scheduled for June 11, aiming to leverage his over 30 years of pharmaceutical industry experience to strengthen leadership and support the company's transformation and profitability.
- Succession Plan Implementation: Weinand will succeed Iris Löw-Friedrich, whose term ends at the 2026 Annual General Meeting, marking a strategic succession process that ensures continuity and stability in leadership during a critical transformation phase.
- Strategic Focus: Having previously served as a member of Bayer AG's Management Board and held CEO roles at Bayer Pharmaceuticals, Weinand's extensive industry background is expected to enhance Evotec's commercial execution and strategic partnerships.
- Stock Price Increase: Evotec closed up 1.16% at $2.6200 on Monday, with after-hours trading rising an additional 1.91%, reflecting positive market sentiment towards the new chairman nomination and potentially boosting investor confidence.
See More
Evotec Appoints New Chief Commercial Officer
- Executive Appointment: Evotec SE has appointed Dr. Ashiq H. Khan as Chief Commercial Officer, who brings over 15 years of international leadership experience and will lead the development of a globally integrated commercial organization aligned with the company's scientific leadership to enhance customer value and drive sustainable growth.
- Extensive Industry Experience: Dr. Khan has a distinguished track record in biotech, CRO, and AI-driven platforms, having successfully managed transcontinental teams and closed over $7 billion in high-value agreements, which will significantly bolster Evotec's commercial strategy.
- Innovation-Driven Transformation: CEO Dr. Christian Wojczewski emphasized that Dr. Khan's success in robotics, AI, and drug discovery platforms is crucial for executing the next phase of Evotec's transformation into a responsive drug discovery and development engine focused on high-value services.
- Integration of Technology and Science: Dr. Khan stated that Evotec is uniquely positioned to advance early-stage drug discovery and development, leveraging industry-validated platforms and deep scientific expertise to drive the next generation of breakthrough therapies, thereby enhancing the company's competitive edge in the market.
See More
Evotec CFO Paul Hitchin Resigns, Claire Hinshelwood Appointed
- Executive Change: Evotec SE announced that CFO Paul Hitchin will resign on April 30, citing personal reasons unrelated to the company, indicating potential challenges in executive stability.
- New Financial Chief: Claire Hinshelwood will take over as CFO on May 1, bringing over 30 years of financial leadership experience, particularly from her recent role as CFO at BMI Group, which is expected to introduce new financial strategies for the company.
- Stock Price Reaction: On Nasdaq, Evotec's shares rose 1.55% in after-hours trading to $3.28, reflecting market optimism regarding the new CFO's appointment, despite closing at $3.23 during regular trading.
- Market Confidence: Although executive changes can introduce uncertainty, the market's response suggests that investors maintain a positive outlook on Evotec's future financial management and strategic direction, which may influence its long-term stock performance.
See More
Evotec Appoints New Chief Operating Officer
- Executive Appointment: Evotec announced the appointment of Dr. Ingrid Müller as Chief Operating Officer, effective May 1, 2026, bringing over 20 years of international leadership experience to oversee global operations and the execution of the Horizon initiative.
- Strategic Execution: In her previous role as Vice President at CureVac, Dr. Müller successfully drove portfolio strategy and execution, and in senior roles at Sanofi and Fresenius Kabi, she strengthened supply chain resilience and achieved annual savings.
- Operational Efficiency Enhancement: As COO, Dr. Müller will focus on improving quality, productivity, and delivery capabilities, with expectations that her extensive operational and strategic background will drive Evotec's growth transformation and enhance its competitiveness in the life sciences sector.
- Global Team Collaboration: Dr. Müller expressed her eagerness to collaborate with the global team to further enhance operational excellence and quality, supporting Evotec's sustainable growth and reflecting the company's commitment to scientific and technological platforms.
See More
Evotec (EVO) Q3 2025 Earnings Call Transcript
See More
Evotec SE Reports Significant Revenue and Cost Savings in 2025
- Revenue Growth: In Q4 2025, Evotec SE reported a revenue increase of EUR 32.1 million, or 14.5%, reaching EUR 253.3 million, indicating strong market performance despite a slight 1.1% decline in full-year revenue.
- Significant EBITDA Improvement: Adjusted EBITDA surged by EUR 29.5 million, or 103.6%, to EUR 58 million in Q4 2025, reflecting substantial operational efficiency improvements that enhance financial resilience.
- Cost Savings Achieved: Evotec delivered over EUR 60 million in annualized cost savings in 2025 and reduced capital expenditures by approximately 60%, providing more funding for future investments and growth opportunities.
- Strategic Partnership Agreements: The $650 million agreement with Sandoz and milestone payments from BMS signify crucial advancements in Evotec's global health programs, expected to drive future revenue growth.
See More
Evotec Nominates New Chairman for Supervisory Board
- Board Leadership Change: Evotec SE has nominated Dieter Weinand as Chairman of the Supervisory Board, with the election scheduled for June 11, aiming to leverage his over 30 years of pharmaceutical industry experience to strengthen leadership and support the company's transformation and profitability.
- Succession Plan Implementation: Weinand will succeed Iris Löw-Friedrich, whose term ends at the 2026 Annual General Meeting, marking a strategic succession process that ensures continuity and stability in leadership during a critical transformation phase.
- Strategic Focus: Having previously served as a member of Bayer AG's Management Board and held CEO roles at Bayer Pharmaceuticals, Weinand's extensive industry background is expected to enhance Evotec's commercial execution and strategic partnerships.
- Stock Price Increase: Evotec closed up 1.16% at $2.6200 on Monday, with after-hours trading rising an additional 1.91%, reflecting positive market sentiment towards the new chairman nomination and potentially boosting investor confidence.
See More
Evotec Appoints New Chief Commercial Officer
- Executive Appointment: Evotec SE has appointed Dr. Ashiq H. Khan as Chief Commercial Officer, who brings over 15 years of international leadership experience and will lead the development of a globally integrated commercial organization aligned with the company's scientific leadership to enhance customer value and drive sustainable growth.
- Extensive Industry Experience: Dr. Khan has a distinguished track record in biotech, CRO, and AI-driven platforms, having successfully managed transcontinental teams and closed over $7 billion in high-value agreements, which will significantly bolster Evotec's commercial strategy.
- Innovation-Driven Transformation: CEO Dr. Christian Wojczewski emphasized that Dr. Khan's success in robotics, AI, and drug discovery platforms is crucial for executing the next phase of Evotec's transformation into a responsive drug discovery and development engine focused on high-value services.
- Integration of Technology and Science: Dr. Khan stated that Evotec is uniquely positioned to advance early-stage drug discovery and development, leveraging industry-validated platforms and deep scientific expertise to drive the next generation of breakthrough therapies, thereby enhancing the company's competitive edge in the market.
See More
